Clinical Trial

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-10-06 -> 2027-10-06 2026-05-16
minor Completion pushed: 2025-10-09 -> 2027-12-09 2026-05-16
Trial Details
NCT Number NCT06736275
Lead Sponsor Jiangsu Nutai Biologics Co., Ltd
Collaborators: Chinese Academy of Medical Sciences, Jiangsu GQ Pharma Co., Ltd.
Conditions Advanced Cancer, Cachexia
Enrollment 28 participants
Start Date 2024-09-02
Primary Completion 2027-10-06 (estimated)
Study Completion 2027-12-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-15